Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateSector Deep DivesUploadPipelinePE CyclesBrainAbout

Data updated weekly. Not financial advice.

Sector Alpha
  1. Home
  2. /Momentum
  3. /Speciality Chemicals
  4. /Tatva Chintan Pharma Chem Ltd
MomentumDeep Value

Tatva Chintan Pharma Chem Ltd: Stock Analysis & Fundamentals

Updated this week

Tatva Chintan Pharma Chem Ltd (Speciality Chemicals) — fundamental analysis, earnings data, and key metrics. PE: 67.1. ROE: 5.5%. This stock is not currently in the Nifty 500 momentum outperformers list.

Tatva Chintan Pharma Chem Ltd Key Facts

What's Happening

💪Debt reduced 31% YoY — balance sheet strengthening
🏛️DII reducing — stake down 3.0%

Key Numbers

Current Price
₹1,206
Dividend Yield
0.08%
Market Cap
2.8K Cr
Valuation
N/A

Other Top Speciality Chemicals Stocks Beating Nifty 500

Pidilite Industries Ltd
Average
+9.6%
Aether Industries Ltd
Weak • 12w streak
+6.8%
Privi Speciality Chemicals Ltd
Average • 11w streak
+12.2%
Neogen Chemicals Ltd
Average • 9w streak
+48.4%
Fineotex Chemical Ltd
Average • 4w streak
+85.2%
← Back to Speciality ChemicalsDashboard

Frequently Asked Questions: Tatva Chintan Pharma Chem Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Tatva Chintan Pharma Chem Ltd's latest quarterly results?

Tatva Chintan Pharma Chem Ltd's latest quarterly results (Mar 2026) show

  • PAT Growth YoY: +900.0%
  • Revenue Growth YoY: +24.1%
  • Operating Margin: 21.0%

What is Tatva Chintan Pharma Chem Ltd's current PE ratio?

Tatva Chintan Pharma Chem Ltd's current PE ratio is 67.1x.

  • Current PE: 67.1x
  • Market Cap: 2.8K Cr
  • Dividend Yield: 0.08%

What is Tatva Chintan Pharma Chem Ltd's price-to-book ratio?

Tatva Chintan Pharma Chem Ltd's price-to-book ratio is 3.6x.

  • Price-to-Book (P/B): 3.6x
  • Book Value per Share: ₹334
  • Current Price: ₹1206

Is Tatva Chintan Pharma Chem Ltd a fundamentally strong company?

Tatva Chintan Pharma Chem Ltd's fundamental strength based on key financial ratios

  • Return on Capital (ROCE): 7.0%

Is Tatva Chintan Pharma Chem Ltd debt free?

Tatva Chintan Pharma Chem Ltd has a debt-to-equity ratio of N/A.

  • Total Debt: ₹120 Cr

What is Tatva Chintan Pharma Chem Ltd's return on equity (ROE) and ROCE?

Tatva Chintan Pharma Chem Ltd's return ratios over recent years

  • FY2024: ROCE 7.0%
  • FY2025: ROCE 1.0%
  • FY2026: ROCE 7.0%

Is Tatva Chintan Pharma Chem Ltd's cash flow positive?

Tatva Chintan Pharma Chem Ltd's operating cash flow is positive (FY2026).

  • Cash from Operations (CFO): ₹31 Cr
  • Free Cash Flow (FCF): ₹-85 Cr
  • CFO/PAT Ratio: 74% (adequate)

What is Tatva Chintan Pharma Chem Ltd's dividend yield?

Tatva Chintan Pharma Chem Ltd's current dividend yield is 0.08%.

  • Dividend Yield: 0.08%
  • Current Price: ₹1206

Who holds Tatva Chintan Pharma Chem Ltd shares — promoters, FII, DII?

Tatva Chintan Pharma Chem Ltd's shareholding pattern (Mar 2026)

  • Promoters: 72.0%
  • FII (Foreign): 3.8%
  • DII (Domestic): 3.0%
  • Public: 21.2%

Is promoter holding increasing or decreasing in Tatva Chintan Pharma Chem Ltd?

Tatva Chintan Pharma Chem Ltd's promoter holding has remained stable recently.

  • Current Promoter Holding: 72.0% (Mar 2026)
  • Previous Quarter: 72.0% (Dec 2025)
  • Change: 0.00% (stable)

Is Tatva Chintan Pharma Chem Ltd a new momentum entry or an established outperformer?

Tatva Chintan Pharma Chem Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Tatva Chintan Pharma Chem Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Tatva Chintan Pharma Chem Ltd may be worth studying

  • Cash flow is positive — CFO ₹31 Cr

What is the investment thesis for Tatva Chintan Pharma Chem Ltd?

Tatva Chintan Pharma Chem Ltd investment thesis summary:

What is the future outlook for Tatva Chintan Pharma Chem Ltd?

Tatva Chintan Pharma Chem Ltd's forward outlook based on current data signals

  • Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.